Therapeutic targeting of MALT1 protease activity might therefore become a promising approach for the treatment of MALT lymphomas and other B cell lymphomas associated with deregulated NF-κB signaling [104]. This evidence concerns the gene NFKB1 and B-cell non-Hodgkin lymphoma.